公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2020 | Two-year follow-up of a randomized phase III clinical trial of nivolumab vs. the investigator's choice of therapy in the Asian population for recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141) | Yen C.-J.; Kiyota N.; Hanai N.; Takahashi S.; Yokota T.; Iwae S.; Shimizu Y.; RUEY-LONG HONG ; Goto M.; Kang J.-H.; Li W.S.K.; Ferris R.L.; Gillison M.; Endo T.; Jayaprakash V.; Tahara M. | Head and Neck | 25 | 19 |